| Abstract: |
Mitoguazone (methylglyoxal-bis(guanyl-hydrazone), MGBG) was studied by its first-pass mechanism in both cancer patients and experimental cancer models. It appears from the study that 90% of MGBG is cleared from the plasma within minutes. 24-h recovery in the urine, however, did not exceed 16% so that 84% of the drug seems to be bound to subcellular compartments. Tissue levels of MGBG in the normal prostate ranged higher than in experimental prostate cancer type 3327 M/G, i.e. enhanced clearance from cancer tissues: polyamine biosynthetic enzymes, ornithin decarboxylase as well as S-adenosylmethionine decarboxylase are contrarily affected by MGBG. |
| Keywords: |
cancer chemotherapy; clinical article; methodology; adenocarcinoma; mouse; animal; mice; cells, cultured; drug administration schedule; cell line; animal experiment; dose-response relationship, drug; kidney carcinoma; kidney neoplasms; prostatic neoplasms; mice, inbred strains; kidney; tissue distribution; carcinoma, renal cell; rat; drug clearance; drug tissue level; rats; prostate adenocarcinoma; drug blood level; therapy; clinical trials; infusions, parenteral; intravenous drug administration; pharmacokinetics; mitoguazone; drug urine level; human experiment; intraperitoneal drug administration; ornithine decarboxylase; rats, inbred strains; male genital system; cancer; human; male; priority journal; support, non-u.s. gov't; adenosylmethionine decarboxylase; mitoguazone c 14
|
